Key facts
- A2 Bio’s last known valuation is $280.0M (Jan 2025).
- It has raised $352.9M; the latest was Later Stage VC ($80.0M) in Jan 2025.
- Notable investors include Mana Ventures, StepStone Group, S32, Samsara BioCapital, Casdin Capital — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for A2 Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for A2 Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About A2 Bio
Developer of a cell therapy designed to cure cancer via tumor-specific targeting. The company engineers tumor cells that target the loss of genetic material in tumors through the selective killing of tumor cells while leaving normal cells unharmed, enabling physicians to revolutionize the treatment of solid tumors.
- Sector
- Healthcare
- HQ
- Agoura Hills, CA, United States
- Founded
- 2017
- Employees
- 124
- Website
- a2bio.com/
- Ownership
- Privately Held (backing)
A2 Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in A2 Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on A2 Bio in its N-PORT filings yet. We sweep new filings monthly.